{Reference Type}: Journal Article
{Title}: Topical Imiquimod in Primary Cutaneous Extramammary Paget's Disease: A Systematic Review.
{Author}: Mayo-Martínez F;Moro R;Millán-Esteban D;Ríos-Viñuela E;Bautista IJ;Nagore E;Sanmartín O;Llombart B;
{Journal}: Cancers (Basel)
{Volume}: 15
{Issue}: 23
{Year}: 2023 Nov 30
{Factor}: 6.575
{DOI}: 10.3390/cancers15235665
{Abstract}: Extramammary Paget's disease (EMPD) is subclinical in extent and multifocal in nature. There is no global consensus for treatment, so its management represents a challenge in clinical practice. Therefore, we conducted a systematic review through the main electronic databases to assess the effectiveness of topical imiquimod in cutaneous EMPD and to discuss its management. Finally, 24 studies involving a total of 233 EMPD patients treated with topical imiquimod were selected. The topical imiquimod response rate was 67%, and the complete response (CR) rate was 48%. Patients were treated with a three-four times a week regimen in most cases, ranging between 2 to 52 weeks. In addition, imiquimod was applied as an adjunctive treatment in 21 patients, achieving a CR rate of 71%. Consequently, imiquimod therapy could achieve a good response ratio as a first-line treatment, as adjuvant and neo-adjuvant therapy, and as a treatment for recurrent disease. The heterogeneity between studies and the lack of a control arm made it impossible to conduct a meta-analysis. To improve the quality of evidence on EMPD, multicenter studies are essential to collect a larger number of patients and, consequently, obtain high-quality evidence to standardize treatment. The Prospero registration number is CRD42023447443.